Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Luciano, Stumbo"'
Publikováno v:
Clinical Management Issues, Vol 4, Iss 1S, Pp 3-7 (2015)
We report the case of a 51-year-old woman with limited Small Cell Lung Cancer (SCLC). Cytological diagnosis has been made by fibroscopy. Chemotherapy schedule was cisplatin 30 mg/mq and VP-16 100 mg/mq days 1,2,3 q21 as first line treatment. The seru
Externí odkaz:
https://doaj.org/article/b25af28d89884b4b849884a47f771108
Autor:
Giampietro Gasparini, Fiamma Buttitta, Mario Rosario D'Andrea, Salvatore Tumolo, Angela Buonadonna, Ida Pavese, Stefano Cordio, Michele De Tursi, Stefania Mosconi, Luciano Stumbo, Lara Felicioni, Antonio Marchetti
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 9, Pp 751-756 (2014)
PURPOSE: To improve the selection of advanced colorectal cancer patients to panitumumab by optimizing the assessment of RAS (KRAS-NRAS) mutations. EXPERIMENTAL DESIGN: Using a centralized pyrosequencing RAS assay, we analyzed the tumors of 94 patient
Externí odkaz:
https://doaj.org/article/ec0682c3d48543418683dc3b06e25e8f
Publikováno v:
Expert Review of Quality of Life in Cancer Care. 1:421-423
Cancer patient can present a set of physical problems, psychosocial and spiritual needs that require additional and specific treatments. The critical factor that presents itself is the planning of an appropriate program of care and treatment defined
Publikováno v:
Clinical Management Issues; Vol 4, No 1S (2010); 3-7
Clinical Management Issues, Vol 4, Iss 1S, Pp 3-7 (2015)
Clinical Management Issues, Vol 4, Iss 1S, Pp 3-7 (2015)
We report the case of a 51-year-old woman with limited Small Cell Lung Cancer (SCLC). Cytological diagnosis has been made by fibroscopy. Chemotherapy schedule was cisplatin 30 mg/mq and VP-16 100 mg/mq days 1,2,3 q21 as first line treatment. The seru
Autor:
Marianna Silletta, Delia De Lisi, Luciano Stumbo, Giuseppe Badalamenti, G. Maltese, Anna Maria Frezza, Daniele Santini, Mariella Spalato Ceruso, Linda Cerbone, Giuseppe Tonini, Bruno Vincenzi
Publikováno v:
Scientific Reports
Elevation in liver transaminases is common in patients treated with the marine antitumor agent trabectedin. However, the impact of trabectedin-related transaminase elevations on treatment outcomes is unclear. This retrospective study investigated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6228befffef4a7167010acc04d799348
http://hdl.handle.net/10447/209456
http://hdl.handle.net/10447/209456
Autor:
Bruno Vincenzi, Daniele Santini, Alice Zoccoli, Loretta D'Onofrio, Michele Iuliani, Francesco Pantano, Vladimir Virzì, Giuseppe Tonini, Giulia Ribelli, Luciano Stumbo, Chiara Spoto, Marco Fioramonti
Publikováno v:
Breast Cancer Research : BCR
Breast cancer research, 17
Breast cancer research, 17
Bisphosphonates (BPs) are approved as standard therapy in breast cancer for the treatment of bone metastases, since they were demonstrated to reduce the prevalence of skeletal-related events including fractures and hypercalcemia. In the adjuvant sett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b96a8d4b1095f575987c0b8be071075
http://hdl.handle.net/11573/1641535
http://hdl.handle.net/11573/1641535
Autor:
Rita, De Sanctis, Silvia, Quadrini, Flavia, Longo, Vittoria, Lapadula, Rossella, Restuccia, Ester, Del Signore, Lucilla, De Filippis, Luciano, Stumbo, Bruno, Gori, Vincenzo, Bianco, Iolanda, Speranza, Maria Luisa, Basile, Marisa, Di Seri
Aims and background Capecitabine is the reference treatment for anthracycline-and/or taxane-pretreated metastatic breast cancer (MBC). This study examined its efficacy, tolerability and impact on the quality of life of elderly patients with MBC. Mate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d66ec58c1d09ede2d8233eee2dfd3c27
http://hdl.handle.net/11573/872710
http://hdl.handle.net/11573/872710
Autor:
Salvatore Tumolo, Mario D'Andrea, Domenico Bilancia, Antonio Marchetti, Roberto Labianca, Giampietro Gasparini, V. Leonardi, Lara Felicioni, G. Sanna, Angela Buonadonna, Mario Airoldi, Roberto Bordonaro, Luciano Stumbo, Ida Pavese, Stefano Jacobelli
Publikováno v:
Annals of Oncology. 24:iv93
Autor:
Michele De Tursi, Fiamma Buttitta, Mario D'Andrea, Ida Pavese, Lara Felicioni, Antonio Marchetti, Salvatore Tumolo, Stefano Cordio, Luciano Stumbo, Stefania Mosconi, Giampietro Gasparini, Angela Buonadonna
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 9, Pp 751-756 (2014)
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 9, Pp 751-756 (2014)
PURPOSE: To improve the selection of advanced colorectal cancer patients to panitumumab by optimizing the assessment of RAS (KRAS-NRAS) mutations. EXPERIMENTAL DESIGN: Using a centralized pyrosequencing RAS assay, we analyzed the tumors of 94 patient
Autor:
Simone Scarlata, Marco Caricato, Luciano Stumbo, Aldo Pezzuto, Marco Russano, Pierfilippo Crucitti, Giuseppe Tonini
Publikováno v:
Scopus-Elsevier
Background: Erlotinib is a validated drug “for the treatment of patients affected by advanced unresectable non small cell lung cancer (NSCLC) with EGFR mutations”. We want to focus on potential functional benefits deriving from a combined therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9024c98a470cc03395c8e85d326fff2c
http://www.scopus.com/inward/record.url?eid=2-s2.0-84947813665&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-84947813665&partnerID=MN8TOARS